These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 15922119)

  • 21. Olmesartan blocks inflammatory reactions in endothelial cells evoked by advanced glycation end products by suppressing generation of reactive oxygen species.
    Yamagishi S; Matsui T; Nakamura K; Inoue H; Takeuchi M; Ueda S; Okuda S; Imaizumi T
    Ophthalmic Res; 2008; 40(1):10-5. PubMed ID: 18025836
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibitory effect of GSPE on RAGE expression induced by advanced glycation end products in endothelial cells.
    Zhang FL; Gao HQ; Shen L
    J Cardiovasc Pharmacol; 2007 Oct; 50(4):434-40. PubMed ID: 18049312
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mechanisms of disease: advanced glycation end-products and their receptor in inflammation and diabetes complications.
    Yan SF; Ramasamy R; Schmidt AM
    Nat Clin Pract Endocrinol Metab; 2008 May; 4(5):285-93. PubMed ID: 18332897
    [TBL] [Abstract][Full Text] [Related]  

  • 24. AGE, RAGE, and ROS in diabetic nephropathy.
    Tan AL; Forbes JM; Cooper ME
    Semin Nephrol; 2007 Mar; 27(2):130-43. PubMed ID: 17418682
    [TBL] [Abstract][Full Text] [Related]  

  • 25. DNA-aptamers raised against AGEs as a blocker of various aging-related disorders.
    Yamagishi S; Taguchi K; Fukami K
    Glycoconj J; 2016 Aug; 33(4):683-90. PubMed ID: 27338620
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Possible involvement of tobacco-derived advanced glycation end products (AGEs) in an increased risk for developing cancers and cardiovascular disease in former smokers.
    Yamagishi S; Matsui T; Nakamura K
    Med Hypotheses; 2008 Aug; 71(2):259-61. PubMed ID: 18448262
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Olmesartan blocks advanced glycation end products (AGEs)-induced angiogenesis in vitro by suppressing receptor for AGEs (RAGE) expression.
    Yamagishi S; Matsui T; Nakamura K; Inoue H; Takeuchi M; Ueda S; Fukami K; Okuda S; Imaizumi T
    Microvasc Res; 2008 Jan; 75(1):130-4. PubMed ID: 17560613
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Benazepril, an angiotensin-converting enzyme inhibitor, alleviates renal injury in spontaneously hypertensive rats by inhibiting advanced glycation end-product-mediated pathways.
    Liu XP; Pang YJ; Zhu WW; Zhao TT; Zheng M; Wang YB; Sun ZJ; Sun SJ
    Clin Exp Pharmacol Physiol; 2009 Mar; 36(3):287-96. PubMed ID: 19018797
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Minodronate, a nitrogen-containing bisphosphonate, is a promising remedy for treating patients with diabetic retinopathy.
    Yamagishi S; Nakamura K; Matsui T; Takeuchi M
    Med Hypotheses; 2006; 66(2):273-5. PubMed ID: 16216433
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Unique atheroprotective property of azelnidipine, a dihydropyridine-based calcium antagonist.
    Nakamura K; Yamagishi S; Inoue H
    Med Hypotheses; 2005; 65(1):155-7. PubMed ID: 15893134
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of advanced glycation end products (AGEs) and oxidative stress in vascular complications in diabetes.
    Yamagishi S; Maeda S; Matsui T; Ueda S; Fukami K; Okuda S
    Biochim Biophys Acta; 2012 May; 1820(5):663-71. PubMed ID: 21440603
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Calcium antagonists: current and future applications based on new evidence. Calcium antagonists and diabetes].
    Yamagishi S
    Clin Calcium; 2010 Jan; 20(1):77-82. PubMed ID: 20048437
    [TBL] [Abstract][Full Text] [Related]  

  • 33. From molecular footprints of disease to new therapeutic interventions in diabetic nephropathy.
    Miyata T; Yamamoto M; Izuhara Y
    Ann N Y Acad Sci; 2005 Jun; 1043():740-9. PubMed ID: 16037301
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Glycation, inflammation, and RAGE: a scaffold for the macrovascular complications of diabetes and beyond.
    Yan SF; Ramasamy R; Naka Y; Schmidt AM
    Circ Res; 2003 Dec; 93(12):1159-69. PubMed ID: 14670831
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of advanced glycation end products and their receptors in development of diabetic neuropathy.
    Wada R; Yagihashi S
    Ann N Y Acad Sci; 2005 Jun; 1043():598-604. PubMed ID: 16037282
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Convergence and amplification of toll-like receptor (TLR) and receptor for advanced glycation end products (RAGE) signaling pathways via high mobility group B1 (HMGB1).
    van Beijnum JR; Buurman WA; Griffioen AW
    Angiogenesis; 2008; 11(1):91-9. PubMed ID: 18264787
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pathologic role of dietary advanced glycation end products in cardiometabolic disorders, and therapeutic intervention.
    Yamagishi S; Matsui T
    Nutrition; 2016 Feb; 32(2):157-65. PubMed ID: 26602289
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The AGE/RAGE axis in diabetes-accelerated atherosclerosis.
    Jandeleit-Dahm K; Watson A; Soro-Paavonen A
    Clin Exp Pharmacol Physiol; 2008 Mar; 35(3):329-34. PubMed ID: 18290873
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Receptor for Advanced Glycation Endproducts (RAGE): a formidable force in the pathogenesis of the cardiovascular complications of diabetes & aging.
    Yan SF; D'Agati V; Schmidt AM; Ramasamy R
    Curr Mol Med; 2007 Dec; 7(8):699-710. PubMed ID: 18331228
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pigment-epithelium-derived factor suppresses expression of receptor for advanced glycation end products in the eye of diabetic rats.
    Yamagishi S; Matsui T; Nakamura K; Yoshida T; Takeuchi M; Inoue H; Yoshida Y; Imaizumi T
    Ophthalmic Res; 2007; 39(2):92-7. PubMed ID: 17284935
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.